-
1.COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS 审中-公开
Title translation: 化合物是S1P调节剂和/或ATX调节剂公开(公告)号:WO2014025709A1
公开(公告)日:2014-02-13
申请号:PCT/US2013/053669
申请日:2013-08-05
Applicant: BIOGEN IDEC MA INC.
Inventor: GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam , MA, Bin , SUN, Lihong , XIN, Zhili , ZHANG, Lei
IPC: A61K31/381 , C07C229/34 , A61K31/122 , A61K31/661
CPC classification number: C07D211/62 , A61K31/122 , A61K31/192 , A61K31/196 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/439 , A61K31/445 , A61K31/45 , A61K31/46 , A61K45/06 , C07C229/14 , C07C229/48 , C07C2601/14 , C07D211/34 , C07D211/60 , C07D451/02 , C07D451/14 , A61K2300/00
Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
Abstract translation: 式(I)化合物可以调节一种或多种SIP受体的活性和/或自分泌素(ATX)的活性。
-
公开(公告)号:WO2014018887A1
公开(公告)日:2014-01-30
申请号:PCT/US2013/052325
申请日:2013-07-26
Applicant: BIOGEN IDEC MA INC.
Inventor: GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam , MA, Bin , MI, Sha , SHAO, Zhaohui , SUN, Lihong , TAVERAS, Arthur , WANG, Deping , XIN, Zhili , ZHANG, Lei
IPC: A61K31/683 , C07C47/575
CPC classification number: A61K31/662 , A61K31/196 , A61K31/397 , A61K31/435 , A61K31/445 , A61K31/454 , A61K31/47 , A61K31/5375 , A61K31/55 , A61K45/06 , C07B2200/07 , C07C229/46 , C07C229/48 , C07C233/47 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2602/26 , C07D205/04 , C07D207/08 , C07D207/16 , C07D211/34 , C07D211/62 , C07D213/79 , C07D213/80 , C07D215/20 , C07D223/06 , C07D265/30 , C07D401/04 , C07D401/06 , C07F9/38 , C07F9/3808
Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).
Abstract translation: 式(I)化合物可调节自分泌素(ATX)的活性。
-
3.BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY 审中-公开
Title translation: 用于治疗肿瘤,神经病学和免疫学中的人类疾病的有机化合物公开(公告)号:WO2015089327A1
公开(公告)日:2015-06-18
申请号:PCT/US2014/069839
申请日:2014-12-11
Applicant: BIOGEN IDEC MA INC. , SUNESIS PHARMACEUTICALS, INC.
Inventor: HOPKINS, Brian T. , MA, Bin , CHAN, Timothy Raymond , KUMARAVEL, Gnanasambandam , MIAO, Hua , BERTOLOTTI-CIARLET, Andrea , OTIPOBY, Kevin
IPC: C07D471/04 , C07D473/00 , C07D487/04 , C07D513/04 , A61K31/519 , A61K31/52 , A61P25/02 , A61P35/00 , A61P37/00
CPC classification number: C07D487/04 , C07D471/04 , C07D473/00 , C07D513/04 , C07D519/00 , G01N33/573 , G01N2333/9121
Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
Abstract translation: 本发明提供了可用作Bruton酪氨酸激酶抑制剂的化合物及其组合物,并且其表现出所需特性。
-
公开(公告)号:WO2014120764A1
公开(公告)日:2014-08-07
申请号:PCT/US2014/013591
申请日:2014-01-29
Applicant: BIOGEN IDEC MA INC.
Inventor: GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam , LIU, Xiaogao , MA, Bin , PENG, Hairuo
IPC: C07C211/19
CPC classification number: C07C229/14 , A61K31/196 , A61K31/197 , A61K31/198 , A61K31/397 , A61K31/40 , A61K31/445 , A61K31/695 , A61K45/06 , C07C229/48 , C07C229/50 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/26 , C07C2602/44 , C07D205/04 , C07D207/08 , C07D207/16 , C07D211/34 , C07D211/62 , C07F7/0812 , Y02A50/401
Abstract: Compounds of formula (I) can modulate the activity of one or more S 1P receptors. Sphingosine 1-phosphate (S IP) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (EDG) receptor family, namely S1P1, S1P2, S1P3, S1P4, and S1P5 (formerly EDG1, EDG5, EDG3, EDG6 and EDG8). The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (Ga.) subunits and beta-gamma (G()y) dimers.
Abstract translation: 式(I)化合物可调节一种或多种S 1 P受体的活性。 鞘氨醇1-磷酸(SIP)是一种溶血磷脂介质,通过刺激内皮细胞分化基因(EDG)受体家族的五个成员即S1P1,S1P2,S1P3,S1P4和S1P5(以前称为EDG1),诱发多种细胞反应 ,EDG5,EDG3,EDG6和EDG8)。 EDG受体是G蛋白偶联受体(GPCR),刺激通过激活异源三聚体G蛋白α(Ga。)亚基和β-gamma(G()y)二聚体而传播第二信使信号。
-
公开(公告)号:WO2014018881A1
公开(公告)日:2014-01-30
申请号:PCT/US2013/052316
申请日:2013-07-26
Applicant: BIOGEN IDEC MA INC.
Inventor: GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam , MA, Bin , MI, Sha , PENG, Hairuo , SHAO, Zhaohui , SUN, Lihong , TAVERAS, Arthur , WANG, Deping , XIN, Zhili , ZHANG, Lei
IPC: A61K31/015 , A61K31/4375 , A61K31/44
CPC classification number: C07D451/02 , A61K31/136 , A61K31/196 , A61K31/439 , A61K31/445 , A61K31/46 , A61K31/472 , A61K31/4725 , A61K31/5375 , A61K31/55 , A61K45/06 , C07B2200/07 , C07C217/22 , C07C229/46 , C07C229/48 , C07C255/59 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/42 , C07D209/52 , C07D211/34 , C07D211/62 , C07D217/22 , C07D221/22 , C07D223/06 , C07D295/096 , C07D401/06 , C07D471/08 , Y02A50/401
Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
Abstract translation: 公开了式(I)的双环芳基化合物,其可以调节自分泌素(ATX)酶的活性。 本发明还涉及作为ATX抑制剂的化合物,以及制备和使用这些化合物治疗由于损伤或疾病引起的脱髓鞘以及治疗增殖性疾病如癌症的方法。
-
公开(公告)号:WO2012109108A1
公开(公告)日:2012-08-16
申请号:PCT/US2012/023799
申请日:2012-02-03
Applicant: BIOGEN IDEC MA INC. , THOMAS, Jermaine , MI, Sha , LIN, Edward, Yin-shiang , ZHENG, Guo, Zhu , MA, Bin , CALDWELL, Richard, D. , GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam
Inventor: THOMAS, Jermaine , MI, Sha , LIN, Edward, Yin-shiang , ZHENG, Guo, Zhu , MA, Bin , CALDWELL, Richard, D. , GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam
IPC: A01N43/40 , A61K31/445
CPC classification number: A61K31/445 , A61K31/225 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/517 , A61K31/55 , A61K31/695 , A61K38/21 , A61K39/3955 , C07D211/34 , C07D211/60 , C07D211/62 , C07D215/20 , C07D401/06 , C07D405/12 , C07K16/2842
Abstract: Compounds of formula (I) or (II) can modulate the activity of SIP receptors.
Abstract translation: 式(I)或(II)的化合物可以调节SIP受体的活性。
-
7.
公开(公告)号:WO2011017561A1
公开(公告)日:2011-02-10
申请号:PCT/US2010/044607
申请日:2010-08-05
Applicant: BIOGEN IDEC MA INC. , THOMAS, Jermaine , LIU, Xiaogao , LIN, Edward, Yin-Shiang , ZHENG, Guo, Zhu , MA, Bin , CALDWELL, Richard, D. , GUCKIAN, Kevin, M. , KUMARAVEL, Gnanasambandam , TAVERAS, Arthur, G.
Inventor: THOMAS, Jermaine , LIU, Xiaogao , LIN, Edward, Yin-Shiang , ZHENG, Guo, Zhu , MA, Bin , CALDWELL, Richard, D. , GUCKIAN, Kevin, M. , KUMARAVEL, Gnanasambandam , TAVERAS, Arthur, G.
IPC: A01N43/42
CPC classification number: A61K31/695 , A61K31/085 , A61K31/11 , A61K31/137 , A61K31/165 , A61K31/18 , A61K31/185 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/222 , A61K31/223 , A61K31/235 , A61K31/277 , A61K31/337 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/404 , A61K31/41 , A61K31/428 , A61K31/445 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/517 , A61K31/662 , A61K31/683 , A61K45/06 , C07C43/247 , C07C47/575 , C07C229/14 , C07C229/22 , C07C229/46 , C07C229/48 , C07C237/08 , C07C237/52 , C07C255/54 , C07C309/14 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07D205/04 , C07D207/16 , C07D209/08 , C07D211/60 , C07D211/62 , C07D215/20 , C07D215/227 , C07D217/04 , C07D217/24 , C07D239/74 , C07D257/04 , C07D277/64 , C07D305/08 , C07D401/06 , C07D403/06 , C07D417/06 , C07F7/081 , C07F9/3808 , C07F9/3834 , C07F9/4006
Abstract: Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.
Abstract translation: 提供了在一种或多种S1P受体上具有激动剂活性的化合物。 化合物是鞘氨醇类似物,其在磷酸化之后可以作为S1P受体的激动剂。
-
公开(公告)号:WO2014081752A1
公开(公告)日:2014-05-30
申请号:PCT/US2013/070878
申请日:2013-11-20
Applicant: BIOGEN IDEC MA INC.
Inventor: PENG, Hairuo , LIN, Edward, Yin-shiang , CHAO, Jianhua , XIN, Zhili , MA, Bin , GUCKIAN, Kevin , CHAN, Timothy , KUMARAVEL, Gnanasambandam , TAVERAS, Arthur, G.
IPC: C07D207/08 , C07D211/22 , C07D211/56 , C07D211/62 , C07D211/70 , C07D213/74 , C07D237/22 , C07D239/47 , C07D295/15 , C07D295/155 , C07D401/12 , A61K31/40 , A61K31/451 , A61K31/4545 , A61K31/495
CPC classification number: C07D211/22 , A61K31/451 , A61K31/4545 , A61K31/495 , A61K31/501 , A61K31/506 , A61K45/06 , C07D207/08 , C07D211/56 , C07D211/62 , C07D211/70 , C07D213/74 , C07D237/22 , C07D239/47 , C07D295/15 , C07D295/155 , C07D401/04 , C07D401/12 , C07D403/04
Abstract: Compounds of formula (I) wherein: X is -0-, -S(0) r -, -CH 2 -, or -NR-, wherein r is 0, 1, or 2; X 1 , X 2 , and X 5 are each independently CR 7 or N; one of X 3 or X 4 is C and is attached by a single bond to -L-, and the other is CR 7 or N, provided that no more than three of X 1 , X 2 , X 3 , X or X 5 are N; Ring A is monocyclic C 5-6 scycloalkyl or a 5- to 6-membered monocyclic heterocyclyl comprising from 1 to 5 heteroatoms independently selected from N, S, or 0; wherein Ring A is further optionally substituted with from 1 to 3 R 4 ; provided that Ring A is not morpholinyl, thiomorpholinyl or tetrahydro-2H-pyranyl; L is a bond, -0-, -NR-, -S(0) n -, -CH 2 -,or -C(O)-, wherein n is 0, 1, or 2; 1 2 L 1 is an C 1-8 alkylene, C 3-s cycloalkylene, -CH 2 -L 2 -, or a 3- to 8- membered heterocyclylene comprising 1 to 5; R 1 is C 6-20 alkyl or a monocyclic C 3-8 cycloalkyl; wherein said C 3-8 cycloalkyl is substituted with at least one R 6 and may be optionally substituted with from 1 to 5 additional R 6 substituents, wherein R 6 for each occurrence is independently selected; and R 2 is -C(0)OR 3 , -C(0)N(R 3 )-S(0) 2 R 3 , -S(0) 2 OR 3 , -C(0)NHC(0) R 3 , -Si(0)OH, - B(OH) 2 , -N(R 3 )S(0) 2 R 3 , -S(0) 2 N(R 3 ) 2 , -O-P(O) (OR 3 ) 2 , or -P(0)(OR 3 ) 2 , -CN, - S(0) 2 NHC(0)R 3 , -C(0)NHS(0) 2 R3, - C(0)NHOH, -C(0)NHCN, -CH(CF 3 )OH, -C(CF 3 ) 2 OH, or a selected heteroaryl or heterocyclyl; and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
Abstract translation: 式(I)化合物其中:X为-O - , - S(O)r - , - CH 2 - 或 - NR-,其中r为0,1或2; X 1,X 2和X 5各自独立地为CR 7或N; X 3或X 4中的一个为C并且通过单键连接至-L-,另一个为CR 7或N,条件是X 1,X 2,X 3,X或X 5中不超过3个为N; 环A是单环C 5-6环烷基或包含1至5个独立地选自N,S或0的杂原子的5至6元单环杂环基; 其中环A进一步任选被1至3个R 4取代; 环A不是吗啉基,硫代吗啉基或四氢-2H-吡喃基; L是键,-O - , - NR - , - S(O)n - , - CH 2 - 或-C(O) - ,其中n是0,1或2; 1 2 L 1是C 1-8亚烷基,C 3 - 亚环亚烷基,-CH 2 -L 2 - 或包含1至5的3-至8-元亚杂环基; R1是C6-20烷基或单环C3-8环烷基; 其中所述C 3-8环烷基被至少一个R 6取代,并且可以任选被1至5个另外的R 6取代基取代,其中每次出现的R 6是独立选择的; 并且R 2是-C(O)OR 3,-C(O)N(R 3)-S(O)2 R 3,-S(O)2 OR 3,-C(O)NHC(O)R 3,-Si , - B(OH)2,-N(R3)S(O)2R3,-S(O)2N(R3)2,-OP(O)(OR3)2或-P(0)(OR3)2 ,-CN,-S(O)2 NHC(O)R 3,-C(O)NHS(O)2 R 3,-C(O)NHOH,-C(O)NHCN,-CH(CF 3)OH,-C CF 3)2 OH,或选择的杂芳基或杂环基; 和其药学上可接受的盐可调节一种或多种SIP受体的活性和/或自分泌素(ATX)的活性。
-
9.BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY 审中-公开
Title translation: 用于治疗肿瘤,神经学和免疫学中的人类疾病的双芳基化合物公开(公告)号:WO2015089337A1
公开(公告)日:2015-06-18
申请号:PCT/US2014/069853
申请日:2014-12-11
Applicant: BIOGEN IDEC MA INC. , SUNESIS PHARMACEUTICALS, INC.
Inventor: HOPKINS, Brian, T. , MA, Bin , CHAN, Timothy, Raymond , SUN, Lihong , ZHANG, Lei , KUMARAVEL, Gnanasambandam , LYSSIKATOS, Joseph, P. , KOCH, Kevin , MIAO, Hua
IPC: C07D403/12 , C07D401/14 , C07D413/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D513/04 , A61K31/44 , A61K31/505 , A61K31/506 , A61P25/02 , A61P35/00 , A61P37/00
CPC classification number: C07D403/12 , A61K31/506 , C07D239/30 , C07D401/14 , C07D409/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/04 , C07D495/04 , C07D513/04 , C07F5/027
Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
Abstract translation: 本发明提供了化合物及其组合物,其可用作布鲁顿氏酪氨酸激酶的抑制剂,并表现出其所希望的特征。 p> p> p>
-
公开(公告)号:WO2014018891A1
公开(公告)日:2014-01-30
申请号:PCT/US2013/052329
申请日:2013-07-26
Applicant: BIOGEN IDEC MA INC.
Inventor: GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam , MA, Bin , MI, Sha , PENG, Hairuo , SHAO, Zhaohui , SUN, Lihong , TAVERAS, Arthur , XIN, Zhili , ZHANG, Lei
IPC: A61K31/54
CPC classification number: C07F7/0818 , A61K31/195 , A61K31/196 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/439 , A61K31/451 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K45/06 , C07C211/38 , C07C217/58 , C07C229/46 , C07C229/50 , C07C233/60 , C07C233/61 , C07C235/66 , C07C2102/10 , C07C2102/42 , C07C2102/44 , C07C2102/50 , C07C2103/62 , C07C2601/10 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/42 , C07C2602/44 , C07C2602/46 , C07C2602/50 , C07C2603/62 , C07C2603/74 , C07D205/04 , C07D209/52 , C07D211/14 , C07D213/74 , C07D215/12 , C07D215/20 , C07D215/38 , C07D217/22 , C07D239/42 , C07D241/20 , C07D295/096 , C07D401/04 , C07D401/06 , C07D451/02 , C07D451/14 , C07D471/08 , C07D491/107 , C07F7/0809 , A61K2300/00
Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
-
-
-
-
-
-
-
-
-